A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (vol 109, pg 107, 2019)

Fuchida Shin-ichi; Sunami Kazutaka; Matsumoto Morio; Okumura Hirokazu; Murayama Tohru; Miyamoto Toshihiro; Otsuka Eichi; Fujishima Naohito; Izumi Tohru; Tamaki Shigehisa; Hiramatsu Yasushi; Kuroda Yoshiaki; Shimazaki Chihiro; Akashi Koichi; Harada Mine

首页> 外文期刊>International journal of hematology >A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (vol 109, pg 107, 2019)

【24h】

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (vol 109, pg 107, 2019)

机译：多发性骨髓瘤患者自体PBSCT和维持治疗的二期二期研究（Vol 109，PG 107,2019）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In the original publication of this article, Conflict of interest was published incorrectly. The corrected Conflict of interest is given below for your reading.

机译：在本文的原始出版物中，利益冲突不正确出版。下面给出纠正的利益冲突，以便阅读。

著录项

来源
《International journal of hematology》 |2019年第1期|共1页
作者
Fuchida Shin-ichi; Sunami Kazutaka; Matsumoto Morio; Okumura Hirokazu; Murayama Tohru; Miyamoto Toshihiro; Otsuka Eichi; Fujishima Naohito; Izumi Tohru; Tamaki Shigehisa; Hiramatsu Yasushi; Kuroda Yoshiaki; Shimazaki Chihiro; Akashi Koichi; Harada Mine;
展开▼
作者单位

Japan Community Hlth Care Org Kyoto Kuramaguchi M Dept Hematol Kita Ku 27 Shimofusa Cho Kyoto;

Natl Hosp Org Okayama Med Ctr Okayama Japan;

Natl Hosp Org Nishigunma Natl Hosp Shibukawa Japan;

Toyama Prefectural Cent Hosp Toyama Japan;

Hyogo Canc Ctr Akashi Hyogo Japan;

Kyushu Univ Hosp Fukuoka Fukuoka Japan;

Oita Prefectural Hosp Oita Japan;

Akita Univ Hosp Akita Japan;

Tochigi Canc Ctr Utsunomiya Tochigi Japan;

Ise Red Cross Hosp Ise Japan;

Japanese Red Cross Soc Himeji Hosp Himeji Hyogo Japan;

Hiroshima Univ Hosp Hiroshima Japan;

Japan Community Hlth Care Org Kyoto Kuramaguchi M Dept Hematol Kita Ku 27 Shimofusa Cho Kyoto;

Kyushu Univ Hosp Fukuoka Fukuoka Japan;

Karatsu Higashimatsuura Med Assoc Karatsu Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (vol 109, pg 107, 2019) [J] . Fuchida Shin-ichi, Sunami Kazutaka, Matsumoto Morio, International journal of hematology . 2019,第1期

机译：多发性骨髓瘤患者自体PBSCT和维持治疗的二期二期研究（Vol 109，PG 107,2019）
2. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study [J] . Roussel Murielle, Lauwers-Cances Valerie, Robillard Nelly, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：卡非佐米，来那度胺和地塞米松（KRd）诱导的一线治疗，然后是新诊断的多发性骨髓瘤（NDMM）患者的自体干细胞移植，Krd合并和来那度胺维持：组间法语国语双歧双歧（IFM）Krd II期研究的主要结果
3. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial [J] . Alina Striha, A. John Ashcroft, Anna Hockaday, Trials . 2018,第1期

机译：ixazomib在复发性多发性骨髓瘤患者中作为挽救性自体干细胞移植（ASCT）的增强条件疗法以及ASCT后巩固和维持策略的作用（ACCoRd [UK-MRA Myeloma XII]试验）： III期随机对照试验
4. Reconstitution of B Lineage Cells After Auto- PBSCT in Patients with Multiple Myeloma [C] . M. Feliksbrot, M.A. Krol, J. Dwilewicz-Trojaczek European Haematology Association . 2002

机译：多发性骨髓瘤患者自身PBSCT后重建B谱系细胞
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd UK-MRA Myeloma XII trial): study protocol for a Phase III randomised controlled trial [O] . Alina Striha, A. John Ashcroft, Anna Hockaday, 2018

机译：ixazomib在复发性多发性骨髓瘤患者中作为挽救性自体干细胞移植（ASCT）的增强条件疗法以及ASCT后巩固和维持策略的作用（ACCoRd UK-MRA Myeloma XII试验）： III期随机对照试验
7. Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma [O] . Shin-ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, 2018

机译：校正至：多发性骨髓瘤患者自体PBSCT后乙二胺固结和维持治疗的II期研究

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (vol 109, pg 107, 2019)

摘要

著录项

相似文献

相关主题

期刊订阅